Adherium Ltd. (AU:ADR) has released an update.
Adherium Limited has announced a significant partnership with AstraZeneca, which will see its Hailie Smartinhaler platform deployed in a clinical trial, marking a strategic move to enhance patient care through high-tech monitoring of respiratory diseases. The deal, valued at $1.1 million over three years, highlights Adherium’s role as a key player in digital health solutions for respiratory conditions, providing tools for clinicians and patients to track medication usage and improve treatment outcomes.
For further insights into AU:ADR stock, check out TipRanks’ Stock Analysis page.
